Antliabio 112
Alternative Names: Antliabio-112Latest Information Update: 26 Apr 2023
At a glance
- Originator Antlia Bioscience
- Class Cardiovascular therapies; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Chronic heart failure
Most Recent Events
- 10 Apr 2023 XL-protein’s proprietary PASylation® technology has a patent protection worldwide including in Europe, in the US, Japan as well as several other countries and territories (Antlia Bioscience pipeline, April 2023)
- 10 Apr 2023 Preclinical trials in Chronic heart failure in USA (Parenteral), prior to April 2023 (Antlia Bioscience pipeline, April 2023)
- 15 Oct 2020 Antlia Bioscience in-licenses PASylation®technology from XL-protein GmbH